

PuriCore plc (“PuriCore” or the “Company”)

Results of 2010 Annual General Meeting Including Proposed Share Consolidation

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 30 June 2010 — [PuriCore](#) (LSE: PURI), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces that Resolutions 1 through 13 were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's investor website at <http://investor.puricore.com>.

Following the approval of the Resolutions, the Company's share capital will be consolidated on the basis of 1 new Ordinary Share of 10p each (the “New Ordinary Shares”) for every 10 existing Ordinary Shares of 1p each (the “Existing Ordinary Shares”). An application has been made to the Financial Services Authority for admission of the New Ordinary Shares to the Official List, and it is expected that the New Ordinary Shares will be admitted to trading on the London Stock Exchange at 8.00am on 2 July 2010. Details of the New Ordinary Shares are listed below:

Issued Share Capital: 22,731,043 New Ordinary Shares of 10 pence each

ISIN: GB00B3XBCR18

It is expected that definitive share certificates in respect of the New Ordinary Shares will be dispatched to shareholders by 8 July 2010 and, where applicable, CREST accounts will be credited on 2 July 2010.

Apart from the change in nominal value, the New Ordinary Shares arising on implementation of the consolidation will have the same rights as and rank equally in all respects with the Existing Ordinary Shares, including in respect of voting, dividend, and other rights.

Copies of the resolutions have been filed with the United Kingdom Listing Authority's Document Viewing Facility and are available for inspection at:

The Financial Services Authority
UKLA Document Viewing Facility
25 The North Colonnade
Canary Wharf
London
E14 5HS

Enquiries:

Ben Brewerton	Greg Bosch, CEO
Susan Quigley	Darren Weiss, CFO
Financial Dynamics	PuriCore
+44 (0) 20 7831 3113	+1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of *C.difficile*, *E.coli*, HIV, Human and Animal

Influenza (including H1N1 and H5N1), *Legionella*, *MRSA*, *M.tuberculosis*, Norovirus, and *Salmonella*. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.